Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Vor Biopharma, a US-based developer of treatments for haematological malignancies based on research at Columbia University, has filed for a $150m initial public offering.
Founded in 2015, Vor is working on drug treatments for haematological malignancies, a type of cancer that affects the blood, bone marrow and lymph nodes. Part of the IPO proceeds will fund the completion of a phase 1/2a clinical trial for its lead drug candidate, VOR33,
The company also plans to invest in the clinical development of a second candidate, VCAR33, which is in a phase 1/2 trial for adult acute myeloid leukaemia. The IPO will come after $152m in funding.
Investment manager RA Capital Management led a $110m series B round for Vor in July 2020 that included spinout-focused investment firm Osage University Partners (OUP).
Pharmaceutical firm Johnson & Johnson subsidiary Johnson & Johnson Innovation – JJDC, pharmaceutical company…
